Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer
NCT05992272, Unknown, Charite University, Berlin, Germany
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer | ClinicalTrials.gov |
| NCT number | NCT05992272 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Enrollment | 300 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Charite University, Berlin, Germany | ClinicalTrials.gov |
| Conditions | Alcohol Use Disorder (AUD), Alcoholism, Substance Use Disorders, Smoking, Tobacco, Stress Reaction, Stress | ClinicalTrials.gov |
| Interventions | fMRI imaging (BOLD), sMRI (structure), Trier Social Stress Test, PIT paradigm, Counting Stroop task, No-go Simon task, Stop Signal Task, blood samples, questionnaires for chronic stress, hair samples, saliva samples, EMA assessment, clinical diagnostic | ClinicalTrials.gov |
| First posted | 2023-08-15 | ClinicalTrials.gov |
| Last updated | 2024-08-21 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Neural PIT effect day 1 | Day 1 | blood oxygenation level dependent (BOLD) response, investigation of neuronal activation of the mesolimbic system in AUD patients and controls using 3 Tesla magnetic resonance imaging following Stress or Placebo intervention OR no intervention | ClinicalTrials.gov |
| Primary | Neural PIT effect day 2 | Day 2 | a subsample of subjects has a second assessment with blood oxygenation level dependent (BOLD) response, investigation of neuronal activation of the mesolimbic system in AUD patients and controls using 3 Tesla magnetic resonance imaging following Stress or Placebo intervention | ClinicalTrials.gov |
| Primary | Behavioral PIT effect on performance day 1 | Day 1 | strength of PIT effect assessed with the PIT paradigm. Performance (correct choices) will be recorded. Stronger PIT effects are associated with higher performance (percent correct choices) in congruent versus lower performance in incongruent trials. | ClinicalTrials.gov |
| Primary | Behavioral PIT effect on velocity day 1 | Day 1 | strength of PIT effect assessed with the PIT paradigm. Velocity will be recorded. Stronger PIT effects are associated with higher velocity in conditions with positively valued background stimuli and lower velocity with negatively valued background stimuli. | ClinicalTrials.gov |
| Primary | Behavioral PIT effect on velocity day 2 | Day 2 | a subsample of subjects has a second assessment with the PIT paradigm (parallel version) following Stress or Placebo intervention. At this second day the investigators calculate velocity PIT effect only. | ClinicalTrials.gov |
| Primary | Chronic stress effects on hair cortisol in picogram/milligram | retrospective assessment before PIT testing at Day 1 | chronic stress assessment via: \- hair cortisol measurement (3 cm hair segments) | ClinicalTrials.gov |
| Primary | Chronic stress quenstionnaire 1 | retrospective assessment before PIT testing at Day 1 | chronic stress assessment via: \- Trier Inventory for the Assessment of Chronic Stress (TICS; assessing chronic stress over the last three months, likert scale 0-4, with zero meaning never and four meaning very often; high values stand for more stress)) | ClinicalTrials.gov |
| Primary | Chronic stress quenstionnaire 2 | retrospective assessment before PIT testing at Day 1 | chronic stress assessment via: \- Social Readjustment Rating Scale (SRRS; assessing chronic stress life events of the last year, scaling asking for yes or no. higher values represent more stressful live events over the last year) | ClinicalTrials.gov |
| Primary | Chronic stress quenstionnaire 3 | retrospective assessment before PIT testing at Day 1 | chronic stress assessment via: \- Perceived Stress Scale (PSS; assessing chronic stress over the last month, likert scale 0-4, with zero meaning never and four meaning very often; high values stand for higher perceived stress) | ClinicalTrials.gov |
| Primary | cognitive control Stroop effect | Day 1 | Cognitive control assessment via: \- Counting Stroop task | ClinicalTrials.gov |
| Primary | cognitive control Simon effect | Day 1 | Cognitive control assessment via: No-go Simon task | ClinicalTrials.gov |
| Primary | cognitive control interference effect | Day 1 | Cognitive control assessment via: Stop Signal reaction time task | ClinicalTrials.gov |
| Primary | Acute stress day 1 | Day 1 | Acute stress inducting using: Trier social stress test (TSST) OR placebo (randomized across days between subjects) | ClinicalTrials.gov |
| Primary | Acute stress day 2 | Day 2 | Acute stress inducting using: Trier social stress test (TSST) OR placebo (randomized across days between subjects) | ClinicalTrials.gov |
| Secondary | Saliva cortisol concentration in nmol/litre | Assessment before, during and after TSST (-60 minutes, 0 minutes, +10 minutes, +20 minutes, +30 minutes,+ 50 minutes, +80 minutes) | Acute stress effects in AUD and HC | ClinicalTrials.gov |
| Secondary | alcohol consumption after 12 months | 12 months after testing for behavioral and neural PIT effects | alcohol drinking amount (quantity, frequency) during a follow-up period of 12 months | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36380640 | RESULT | PubMed |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Simon Task | Primary outcome | ConductCognition |
| Stop-Signal Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.